Alkermes Inc (NASDAQ:ALKS) Institutional Investor Sentiment Is 1.12

October 13, 2017 - By Henry Gaston

 Alkermes Inc (NASDAQ:ALKS) Institutional Investor Sentiment Is 1.12

Sentiment for Alkermes Inc (NASDAQ:ALKS)

Alkermes Inc (NASDAQ:ALKS) institutional sentiment increased to 1.12 in 2017 Q2. Its up 0.01, from 1.11 in 2017Q1. The ratio increased, as 118 institutional investors opened new or increased stock positions, while 105 reduced and sold stock positions in Alkermes Inc. The institutional investors in our partner’s database reported: 143.16 million shares, up from 140.52 million shares in 2017Q1. Also, the number of institutional investors holding Alkermes Inc in their top 10 stock positions decreased from 3 to 2 for a decrease of 1. Sold All: 33 Reduced: 72 Increased: 77 New Position: 41.

Alkermes plc is a biopharmaceutical company. The company has market cap of $7.73 billion. The Firm is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. It currently has negative earnings. The Firm has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

The stock decreased 0.08% or $0.04 during the last trading session, reaching $50.29. About 384,813 shares traded. Alkermes Plc (NASDAQ:ALKS) has risen 47.50% since October 13, 2016 and is uptrending. It has outperformed by 30.80% the S&P500.

Wall Street await Alkermes Plc (NASDAQ:ALKS) to release earnings on November, 1. Analysts forecast EPS of $-0.15, up exactly $0.10 or 40.00 % from 2014’s $-0.25 EPS. After posting $-0.13 EPS for the previous quarter, Alkermes Plc’s analysts now forecast 15.38 % negative EPS growth.

Meditor Group Ltd holds 8.99% of its portfolio in Alkermes Plc for 1.03 million shares. Opus Point Partners Management Llc owns 42,623 shares or 2.27% of their US portfolio. Moreover, Jag Capital Management Llc has 2.19% invested in the company for 188,682 shares. The New York-based Roanoke Asset Management Corp Ny has invested 2.09% in the stock. Kelly Lawrence W & Associates Inc Ca, a California-based fund reported 118,100 shares.#img1#

Alkermes Plc (NASDAQ:ALKS) Ratings Coverage

Ratings analysis reveals 73% of Alkermes’s analysts are positive. Out of 11 Wall Street analysts rating Alkermes, 8 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $35 while the high is $85. The stock’s average target of $61.40 is 22.09% above today’s ($50.29) share price. ALKS was included in 26 notes of analysts from September 1, 2015. The rating was maintained by Leerink Swann on Thursday, January 21 with “Outperform”. The stock of Alkermes Plc (NASDAQ:ALKS) earned “Buy” rating by J.P. Morgan on Thursday, June 29. The firm earned “Buy” rating on Tuesday, September 26 by Jefferies. The stock has “Buy” rating by Jefferies on Thursday, August 24. Jefferies maintained it with “Buy” rating and $62 target in Friday, July 29 report. On Friday, January 22 the stock rating was maintained by UBS with “Neutral”. Jefferies maintained Alkermes Plc (NASDAQ:ALKS) rating on Tuesday, June 6. Jefferies has “Buy” rating and $6900 target. Barclays Capital maintained the stock with “Overweight” rating in Wednesday, October 7 report. The stock has “Market Perform” rating by Cowen & Co on Thursday, January 21. As per Thursday, July 27, the company rating was maintained by Cantor Fitzgerald.

More news for Alkermes Plc (NASDAQ:ALKS) were recently published by:, which released: “Alkermes plc (ALKS) Says Patients Switched to its ARISTADA Showed Significant …” on September 18, 2017.‘s article titled: “Alkermes Preliminary Phase 3 Data Leaves A Welcomed Impression” and published on July 05, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.